Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: LJM who wrote (20348)	6/22/2006 6:32:06 PM
From: Icebrg	Respond to of 52153

Pfizer is really in a big hurry to leave this program. According to Gary Lyons during tonight's cc, he estimates that Pfizer has spent between 400 and 500 mUSD on the Indiplon program(s). The estimate for additional costs made by the two companies is somewhere between 10 and 30 mUSD. And Pfizer just says, enough is enough - to this point, but not any further. Either they must feel very confident that they will be able to buy Sepracor or they have decided to leave the sleep market completely. Either way, things look pretty bright for Sepracor at the moment. Pfizer has by the way been involved in the Indiplon project since December 2002, so putting all the blame at the feet of Gary Lyons doesn't seem entirely fair. If there has been a screw-up, I am sure there are two parties who have screwed, and considering Pfizer's supposed regulatory "expertise" they are actually the ones who should take the majority of the blame for today's mess. Erik